nsc-141537 and Fever

nsc-141537 has been researched along with Fever* in 2 studies

Other Studies

2 other study(ies) available for nsc-141537 and Fever

ArticleYear
Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial.
    American journal of clinical oncology, 1986, Volume: 9, Issue:3

    Thirty-three patients with advanced colorectal adenocarcinoma were treated with daily Anguidine i.v. 5 mg/m2 X 5 for 3 weeks. The patients were stratified into two groups: prior chemotherapy and no prior chemotherapy. No responses were noted. Major toxicities were hypotension and fever.

    Topics: Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Drug Evaluation; Fever; Humans; Hypotension; Rectal Neoplasms; Sesquiterpenes; Trichothecenes

1986
Phase II evaluation of anguidine (NSC-141537) for adenocarcinoma of the colon or rectum.
    Cancer clinical trials, 1978,Winter, Volume: 1, Issue:4

    Anguidine was administered in a dose of 5.0 mg/m2 (3.5 mg/m2 for patients with hepatic dysfunction) intravenously daily for 5 days in a phase II evaluation of 19 patients with metastatic adenocarcinoma of the colon or rectum. Courses were repeated every 3 weeks. No responses were observed but five patients had disease stabilization. Toxicity was marked, causing discontinuation of therapy in several patients. Anguidine appears ineffective in patients with metastatic colon or rectal cancer in the dose and schedule used in this study.

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Female; Fever; Humans; Hypotension; Male; Middle Aged; Rectal Neoplasms; Sesquiterpenes; Trichothecenes

1978